Construction of an immune-related genes nomogram for the preoperative prediction of axillary lymph node metastasis in triple-negative breast cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
   PubMed Web of Science ®Google Scholar
• DeSantis CE, Ma J, Goding SA, et al. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439–448.
   PubMed Web of Science ®Google Scholar
• Plevritis SK, Munoz D, Kurian AW, et al. Association of screening and treatment with breast cancer mortality by molecular subtype in US Women, 2000–2012. JAMA. 2018;319(2):154–164.
   PubMed Web of Science ®Google Scholar
• Tobin NP, Harrell JC, Lovrot J, et al. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Ann Oncol. 2015;26(1):81–88.
   PubMed Web of Science ®Google Scholar
• Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–690.
   PubMed Web of Science ®Google Scholar
• Keren L, Bosse M, Marquez D, et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell. 2018;174(6):1373–1387.
   PubMed Web of Science ®Google Scholar
• Cho N, Han W, Han BK, et al. Breast cancer screening with mammography plus ultrasonography or magnetic resonance imaging in women 50 years or younger at diagnosis and treated with breast conservation therapy. JAMA Oncol. 2017;3(11):1495–1502.
   PubMed Web of Science ®Google Scholar
• Shieh Y, Eklund M, Madlensky L, et al. Breast cancer screening in the precision medicine era: risk-based screening in a population-based trial. J Natl Cancer Inst. 2017;5:109.
   Google Scholar
• Lee CH, Dershaw DD, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol. 2010;7(1):18–27.
   PubMed Web of Science ®Google Scholar
• Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014;311(24):2499–2507.
   PubMed Web of Science ®Google Scholar
• Barry P, Vatsiou A, Spiteri I, et al. The spatiotemporal evolution of lymph node spread in early breast cancer. Clin Cancer Res. 2018;24(19):4763–4770.
   PubMed Web of Science ®Google Scholar
• Houvenaeghel G, Sabatier R, Reyal F, et al. Axillary lymph node micrometastases decrease triple-negative early breast cancer survival. Br J Cancer. 2016;115(9):1024–1031.
   PubMed Web of Science ®Google Scholar
• Wang L, Hu X, Wang P, et al. Integrative 3' untranslated region-based model to identify patients with low risk of axillary lymph node metastasis in operable triple-negative breast cancer. Oncologist. 2018;24(1):22–30.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Somerfield MR, Bosserman LD, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. JCO. 2017;35(5):561–564.
   PubMed Web of Science ®Google Scholar
• Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918–926.
   PubMed Web of Science ®Google Scholar
• Tadros AB, Yang WT, Krishnamurthy S, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg. 2017;152(7):665–670.
   PubMed Web of Science ®Google Scholar
• Uno H, Hassett MJ, Wei LJ. Axillary vs sentinel lymph node dissection in women with invasive breast cancer. JAMA. 2018;319(3):306.
   PubMed Web of Science ®Google Scholar
• Xie X, Tan W, Chen B, et al. Preoperative prediction nomogram based on primary tumor miRNAs signature and clinical-related features for axillary lymph node metastasis in early-stage invasive breast cancer. Int J Cancer. 2018;142(9):1901–1910.
   PubMed Web of Science ®Google Scholar
• Balasubramanian I, Fleming CA, Corrigan MA, et al. Meta-analysis of the diagnostic accuracy of ultrasound-guided fine-needle aspiration and core needle biopsy in diagnosing axillary lymph node metastasis. Br J Surg. 2018;105(10):1244–1253.
   PubMed Web of Science ®Google Scholar
• Vieira AF, Dionisio MR, Gomes M, et al. P-cadherin: a useful biomarker for axillary-based breast cancer decisions in the clinical practice. Mod Pathol. 2017;30(5):698–709.
   PubMed Web of Science ®Google Scholar
• Dihge L, Bendahl PO, Ryden L. Nomograms for preoperative prediction of axillary nodal status in breast cancer. Br J Surg. 2017;104(11):1494–1505.
   PubMed Web of Science ®Google Scholar
• Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–945.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461.
   PubMed Web of Science ®Google Scholar
• Kok M, Winer EP, Loi S. Passion for immune checkpoint blockade in triple negative breast cancer: comment on the IMpassion130 study. Ann Oncol. 2019;30(1):13–16.
   PubMed Web of Science ®Google Scholar
• Li CW, Lim SO, Chung EM, et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell. 2018;33(2):187–201.
   PubMed Web of Science ®Google Scholar
• Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50.
   PubMed Web of Science ®Google Scholar
• Karn T, Jiang T, Hatzis C, et al. Association between genomic metrics and immune infiltration in triple-negative breast cancer. JAMA Oncol. 2017;3(12):1707–1711.
   PubMed Web of Science ®Google Scholar
• Denkert C, Liedtke C, Tutt A, et al. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389(10087):2430–2442.
   PubMed Web of Science ®Google Scholar
• Savas P, Virassamy B, Ye C, et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat Med. 2018;24(7):986–993.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Andorf S, Gomes L, et al. ImmPort: disseminating data to the public for the future of immunology. Immunol Res. 2014;58(2–3):234–239.
   PubMed Web of Science ®Google Scholar
• Gong C, Tan W, Chen K, et al. Prognostic value of a BCSC-associated microRNA signature in hormone receptor-positive HER2-negative breast cancer. Ebiomedicine. 2016;11:199–209.
   PubMed Web of Science ®Google Scholar
• Morrow M, Jagsi R, McLeod MC, et al. Surgeon attitudes toward the omission of axillary dissection in early breast cancer. JAMA Oncol. 2018;4(11):1511.
   PubMed Web of Science ®Google Scholar
• Kwa M, Makris A, Esteva FJ. Clinical utility of gene-expression signatures in early stage breast cancer. Nat Rev Clin Oncol. 2017;14(10):595–610.
   PubMed Web of Science ®Google Scholar
• Banerji S, Cibulskis K, Rangel-Escareno C, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012;486(7403):405–409.
   PubMed Web of Science ®Google Scholar
• Lu HM, Li S, Black MH, et al. Association of breast and ovarian cancers with predisposition genes identified by large-scale sequencing. JAMA Oncol. 2018; 5(1):51–57.
   Web of Science ®Google Scholar
• Ma X, Liu Y, Liu Y, et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature. 2018;555(7696):371–376.
   PubMed Web of Science ®Google Scholar
• Qu A, Yang Y, Zhang X, et al. Development of a preoperative prediction nomogram for lymph node metastasis in colorectal cancer based on a novel serum miRNA signature and CT scans. Ebiomedicine. 2018;37:125.
   PubMed Web of Science ®Google Scholar
• Gu Y, Liu Y, Fu L, et al. Tumor-educated B cells selectively promote breast cancer lymph node metastasis by HSPA4-targeting IgG. Nat Med. 2019;25(2):312.
   PubMed Web of Science ®Google Scholar
• Steenbrugge J, Breyne K, Demeyere K, et al. Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer. J Exp Clin Cancer Res. 2018;37(1):191.
   PubMedGoogle Scholar
• Takada K, Kashiwagi S, Goto W, et al. Possibility of avoiding axillary lymph node dissection by immune microenvironment monitoring in preoperative chemotherapy for breast cancer. J Transl Med. 2018;16(1):318.
   PubMedGoogle Scholar
• Olkhanud PB, Damdinsuren B, Bodogai M, et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells. Cancer Res. 2011;71(10):3505–3515.
   PubMed Web of Science ®Google Scholar
• Song YK, Wang Y, Wen YY, et al. MicroRNA-22 suppresses breast cancer cell growth and increases paclitaxel sensitivity by targeting NRAS. Technol Cancer Res Treat. 2018;17:153303381880999.
   Web of Science ®Google Scholar
• Rimawi MF, De Angelis C, Contreras A, et al. Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat. 2018;167(3):731–740.
   PubMed Web of Science ®Google Scholar